The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BEVLiN: Prospective study of the safety and efficacy of first-line bevacizumab (BEV) plus low-dose interferon-α2a (IFN) in patients (pts) with metastatic renal cell carcinoma (mRCC).
B. Melichar
Consultant or Advisory Role - Roche
Honoraria - GlaxoSmithKline; Novartis; Roche
S. Bracarda
Consultant or Advisory Role - Bayer (U); GlaxoSmithKline (U); Novartis (U); Pfizer
Honoraria - Novartis
V. Matveev
No relevant relationships to disclose
I. Rusakov
No relevant relationships to disclose
A. Kaprin
No relevant relationships to disclose
A. Zyryanov
No relevant relationships to disclose
R. Janciauskiene
Honoraria - Roche
E. Fernebro
No relevant relationships to disclose
G. H. Mickisch
Consultant or Advisory Role - AstraZeneca; Bayer; GlaxoSmithKline; Roche; Takeda; Wyeth
Honoraria - Astellas Pharma; AstraZeneca; Bayer; GlaxoSmithKline; Pfizer; Roche; Sanofi ; Takeda; Wyeth
M. E. Gore
Consultant or Advisory Role - Roche
Honoraria - Roche
A. Schulze
Consultant or Advisory Role - PAREXEL International
S. Jethwa
Employment or Leadership Position - Roche
Stock Ownership - Roche
V. Sneller
Employment or Leadership Position - Roche
P. Mulders
No relevant relationships to disclose
J. Bellmunt
Consultant or Advisory Role - Bayer; Novartis; Pfizer; Roche
Stock Ownership - Bayer; Novartis; Pfizer; Roche